This public calendar is issued by the Food and Drug Administration. It lists significant meetings held by designated FDA policy makers with persons outside the executive branch of the federal government.

Official Name: Stephen M. Hahn, M.D., Commissioner of Food and Drugs

No Significant Event

Official Name: Amy Abernethy, M.D., Ph.D, Principal Deputy Commissioner

Event Date: 08/25/2020
Location: Virtual
Subject: Healthcare Information and Management Systems Society (HIMSS) Webinar: Clinical Care and Clinical Research Together
FDA Participant/Group: N/A
Non FDA Participant/Group: Industry, academics, patient groups, and other stakeholders

Official Name: Anand Shah, M.D., Deputy Commissioner for Medical and Scientific Affairs

No Significant Event

Official Name: Anna Abram, Deputy Commissioner for Policy, Legislation, and International Affairs

No Significant Event

Official Name: Jim Sigg, Deputy Commissioner for Operations

No Significant Event

Official Name: Frank Yiannas, Deputy Commissioner for Food Policy and Response

Event Date: 08/26/2020
Location: Virtual
Subject: Food & Beverage Industry Alliance Town Hall
FDA Participant/Group: KARI IRVIN; ANDREAS KELLER; DONALD PRATER; MARK MOORMAN; SHARON MAYL;
Non FDA Participant/Group: Members from the food and beverage industry

Official Name: Lowell Schiller, Principal Associate Commissioner for Policy

No Significant Event

Official Name: Mark Abdoo, Associate Commissioner for Global Policy and Strategy

No Significant Event

Official Name: Judy McMeekin, Associate Commissioner for Regulatory Affairs

No Significant Event

Official Name: John Wagner, Associate Commissioner for External Affairs

No Significant Event

Official Name: RADM Denise Hinton, Chief Scientist

No Significant Event

Official Name: Patrizia Cavazzoni, M.D., Acting Director, Center for Drug Evaluation and Research

No Significant Event

Official Name: Peter Marks, M.D., Ph.D., Director, Center for Biologics Evaluation and Research

Event Date: 08/25/2020
Location: Virtual
Subject: Global Orphan Drug Conference: What’s the Takeaway - How Can Rare Diseases Benefit From the Regulatory Process?
FDA Participant/Group: N/A
Non FDA Participant/Group: Rare disease stakeholders

Event Date: 08/26/2020
Location: Virtual
Subject: HHS Advisory Committee on Blood and Tissue Safety and Availability; Experience of FDA: Blood Products Industry
FDA Participant/Group: NICOLE VERDUN;
Non FDA Participant/Group: Members of the HHS Advisory Committee on Blood and Tissue Safety and Availability, blood products community, and the public

Official Name: Jeffrey Shuren, M.D., J.D., Director, Center for Devices and Radiological Health

No Significant Event

Official Name: Susan T. Mayne, Ph.D., Director, Center for Food Safety and Applied Nutrition

No Significant Event

Official Name: Mitchell R. Zeller, J.D., Director, Center for Tobacco Products

No Significant Event

Official Name: Steven Solomon, Director, Center for Veterinary Medicine

No Significant Event

Official Name: William Slikker, Jr., Ph.D., Director, National Center for Toxicological Research

No Significant Event

Official Name: Stacy Cline Amin, Chief Counsel

No Significant Event